Surgical safety and efficacy of neoadjuvant immunotherapy plus apatinib and chemotherapy in locally advanced gastric cancer

doi:10.3748/wjg.122397

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 33, Issue 2

This Article

(2)

(0)

(114)

Peer-Review Report of This Article

Supplementary Materials of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Jan 14, 2027; 33(2): 122397
Published online Jan 14, 2027. doi: 10.3748/wjg.122397

Table 3 Surgical outcomes, median (interquartile range)/n (%)

Variable	PAC group (n = 92)	PC group (n = 200)	Statistic	P value
Surgical approach			12.922	< 0.001
Laparoscopic gastrectomy	64 (69.6)	94 (47.0)
Open gastrectomy	28 (30.4)	106 (53.0)
ICG-guided laparoscopic surgery (yes)¹	28/64 (43.8)	35/94 (37.2)	0.674	0.412
Resection range				0.808
Proximal gastrectomy	5 (5.4)	10 (5.0)
Distal gastrectomy	27 (29.3)	52 (26.0)
Total gastrectomy	60 (65.2)	138 (69.0)
Reconstruction approach				0.194
Billroth-I	1 (1.1)	11 (5.5)
Billroth-II and Braun anastomosis	25 (27.2)	43 (21.5)
Roux-en-Y anastomosis	61 (66.3)	139 (69.5)
Tubular gastrogastric anastomosis	5 (5.4)	7 (3.5)
Operative time, minutes	228 (180-279)	220 (180-264)	-0.844	0.399
Conversion to open laparotomy (yes)¹	7/64 (10.9)	9/94 (9.6)	0.078	0.780
Intraoperative blood loss, mL	100 (100-150)	100 (80-100)	-4.398	< 0.001
Intraoperative blood transfusion (yes)	10 (10.9)	24 (12.0)	0.078	0.780
Multiorgan excision (yes)	9 (9.8)	16 (8.0)	0.256	0.613
R0 resection (yes)	85 (92.4)	182 (91.0)	0.156	0.693
Proximal margin, cm	3.5 (2.0-5.2)	2.5 (1.5-4.0)	-2.672	0.008
Distal margin, cm	5.7 (2.8-8.8)	5.2 (3.0-8.9)	-0.167	0.867
Number of lymph nodes dissected	26 (22-32)	25 (21-31)	-0.636	0.525

¹Denominators are the number of patients who underwent laparoscopic surgery in each group (programmed cell death protein-1 inhibitors plus apatinib and chemotherapy: n = 64; preoperative chemotherapy: n = 94).

Percentages may not sum to 100% due to rounding. ICG: Indocyanine green; PAC: Programmed cell death protein-1 inhibitors plus apatinib and chemotherapy; PC: Preoperative chemotherapy.

Full Size Table

Citation: Cheng ZW, Wei M, Zhang Y, Liang YZ, Cao WB, Zhao RD, Yan ZB, Sun GR, Cui XH, Yu WB. Surgical safety and efficacy of neoadjuvant immunotherapy plus apatinib and chemotherapy in locally advanced gastric cancer. World J Gastroenterol 2027; 33(2): 122397
URL: https://www.wjgnet.com/1007-9327/full/v33/i2/122397.htm
DOI: https://dx.doi.org/10.3748/wjg.122397

Cheng ZW, Wei M, Zhang Y, Liang YZ, Cao WB, Zhao RD, Yan ZB, Sun GR, Cui XH, Yu WB. Surgical safety and efficacy of neoadjuvant immunotherapy plus apatinib and chemotherapy in locally advanced gastric cancer. World J Gastroenterol 2027; 33(2): 122397 [DOI: 10.3748/wjg.122397]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.